[{"type": "title", "data": "PED SUS buprenorphine-naloxone (Suboxone) Rapid Microdosing Induction"}, {"type": "category", "data": "Admit/Transfer/Discharge"}, {"type": "note", "data": "Ensure PED Acute Opioid Withdrawal PowerPlan has been ordered prior to completing this PowerPlan", "value": ""}, {"type": "note", "data": "Buprenorphine is an opioid and providers should be familiar with College of Physicians and Surgeons of BC Practice Standards on Safe Prescribing of Opioids and Sedatives and BC Centre for Substance Use Guidelines on Treatment of Opioid Use Disorder", "value": ""}, {"type": "note", "data": "Microdosing allows patients to be started on buprenorphine-naloxone (Suboxone) while concurrently using opioids and thus does not require waiting until withdrawal symptoms occur", "value": ""}, {"type": "note", "data": "Providers may alternatively consider the PED SUS Buprenorphine-Naloxone (Suboxone) Standard Induction PowerPlan for patients in moderate to severe withdrawal OR who are at low risk for precipitated withdrawal", "value": ""}, {"type": "category", "data": "Patient Care"}, {"type": "order", "data": "Clinical Opiate Withdrawal Scale", "value": "checked"}, {"type": "sentence", "data": "First 72 hours: Assess subjective cravings or withdrawal symptoms, using COWS scoring if possible, prior to providing each dose of buprenorphine-naloxone, q30min for 1 hour after each dose and q2h while awake"}, {"type": "order", "data": "Notify Treating Provider", "value": "checked"}, {"type": "sentence", "data": "Notify provider immediately if COWS score increases or patient reports worsening withdrawal after receiving buprenorphine-naloxone. Or if withdrawal symptoms are not adequately managed with medication"}, {"type": "order", "data": "Clinical Opiate Withdrawal Scale", "value": "checked"}, {"type": "sentence", "data": "After 72 hours: Document COWS with vital signs"}, {"type": "category", "data": "Medications"}, {"type": "note", "data": "Ensure prior Hydromorphone order has been reviewed", "value": ""}, {"type": "note", "data": "Hydromorphone usual start dose 1-3 mg, requires reassessment for correct dosing", "value": ""}, {"type": "order", "data": "HYDROmorphone", "value": ""}, {"type": "sentence", "data": "mg, PO, q3h, order duration: 48 hour, PRN other (see comment), drug form: tab"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg tab (dosed as buprenorphine)", "value": ""}, {"type": "sentence", "data": "0.5 mg, sublingual, q3h interval, order duration: 24 hour, drug form: tab"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg tab (dosed as buprenorphine)", "value": ""}, {"type": "sentence", "data": "1 mg, sublingual, q3h interval, order duration: 24 hour, drug form: tab"}, {"type": "order", "data": "Notify Treating Provider", "value": "checked"}, {"type": "sentence", "data": "Notify provider if less than 6 doses of 0.5 mg suboxone given in the first 24 hours and/or less then 6 doses of 1 mg suboxone given in the second 24 hours"}, {"type": "order", "data": "buprenorphine-naloxone 8 mg-2 mg tab (dosed as buprenorphine)", "value": ""}, {"type": "sentence", "data": "8 mg, sublingual, qdaily, drug form: tab"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg tab (dosed as buprenorphine)", "value": ""}, {"type": "sentence", "data": "2 mg, sublingual, q2h, PRN other (see comment), drug form: tab"}, {"type": "note", "data": "On day 4: Provider to write a new order for buprenorphine-naloxone daily with dose equal to the total amount of buprenorphine-naloxone administered on the previous day using the PED SUS Buprenorphine-Naloxone (Suboxone) Subsequent Days Standard Induction PowerPlan. Provider to stop buprenorphine-naloxone PRN dosing once total daily dose is stable (typically day 4)", "value": ""}]
